Susan M. Henshall

ORCID: 0000-0002-1293-0091
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Prostate Cancer Treatment and Research
  • Cancer, Lipids, and Metabolism
  • Epigenetics and DNA Methylation
  • Prostate Cancer Diagnosis and Treatment
  • Cancer-related Molecular Pathways
  • Ferroptosis and cancer prognosis
  • Pancreatic and Hepatic Oncology Research
  • Estrogen and related hormone effects
  • Radiopharmaceutical Chemistry and Applications
  • Cancer-related gene regulation
  • Cancer Treatment and Pharmacology
  • Medical Imaging Techniques and Applications
  • HER2/EGFR in Cancer Research
  • Global Public Health Policies and Epidemiology
  • Gene expression and cancer classification
  • Breast Cancer Treatment Studies
  • Health Systems, Economic Evaluations, Quality of Life
  • Ovarian cancer diagnosis and treatment
  • Wnt/β-catenin signaling in development and cancer
  • Cancer Genomics and Diagnostics
  • Cancer Diagnosis and Treatment
  • Urologic and reproductive health conditions
  • Cell Adhesion Molecules Research
  • Cancer Immunotherapy and Biomarkers
  • Molecular Biology Techniques and Applications

Garvan Institute of Medical Research
2007-2023

St Vincent's Hospital Sydney
2000-2023

UNSW Sydney
2008-2023

St Vincent's Clinic
2008-2023

American Society of Clinical Oncology
2021

American Association of Blood Banks
2021

Ministry of Health
2021

Kwame Nkrumah University of Science and Technology
2021

Ghana Health Service
2021

Komfo Anokye Teaching Hospital
2021

We developed a preoperative nomogram for prediction of lymph node metastases in patients with clinically localized prostate cancer.The study was retrospective, nonrandomized analysis 7,014 treated radical prostatectomy at 6 institutions between 1985 and 2000. Exclusion criteria consisted androgen ablation therapy, salvage pretreatment specific antigen (PSA) greater than 50 ng/ml. Preoperative predictors PSA, clinical stage (1992 TNM) biopsy Gleason sum. These were used logistic regression...

10.1097/01.ju.0000091805.98960.13 article EN The Journal of Urology 2003-11-01

Abstract There is emerging evidence that the balance between estrogen receptor-α (ERα) and androgen receptor (AR) signaling a critical determinant of growth in normal malignant breast. In this study, we assessed AR status cohort 215 invasive ductal breast carcinomas. ERα were coexpressed majority (80-90%) tumor cells. Kaplan-Meier product limit analysis multivariate Cox regression showed an independent prognostic factor ERα-positive disease, with low level (less than median 75% positive...

10.1158/0008-5472.can-09-0452 article EN Cancer Research 2009-07-29

Current adjuvant therapies for pancreatic cancer (PC) are inconsistently used and only modestly effective. Because a high proportion of patients who undergo resection PC likely harbor occult metastatic disease, any trials assessing such as radiotherapy directed at locoregional disease significantly underpowered. Stratification based on the probability (and volume) residual could play an important role in design future clinical radiotherapy.We assessed relationships between margin...

10.1200/jco.2008.20.5104 article EN Journal of Clinical Oncology 2009-04-28

Pancreatic ductal adenocarcinoma (PDA) is an extremely aggressive malignancy, which carries a dismal prognosis. Activating mutations of the Kras gene are common to vast majority human PDA. In addition, recent studies have demonstrated that embryonic signaling pathway such as Hedgehog and Notch inappropriately upregulated in this disease. The role another pathway, namely canonical Wnt cascade, still controversial. Here, we use array analysis platform demonstrate general activation arm...

10.1371/journal.pone.0001155 article EN cc-by PLoS ONE 2007-11-06

Abstract Gene expression profiling offers a promising new technique for the diagnosis and prognosis of cancer. We have applied this technology to build clinically robust site origin classifier with ultimate aim applying it determine cancer unknown primary (CUP). A single cDNA microarray platform was used profile 229 metastatic tumors representing 14 tumor types multiple histologic subtypes. This data set subsequently training validation support vector machine (SVM) classifier, demonstrating...

10.1158/0008-5472.can-04-3617 article EN Cancer Research 2005-05-15

PURPOSE: We evaluated the predictive accuracy of a recently published preoperative nomogram for prostate cancer that predicts 5-year freedom from recurrence. applied this to patients seven different institutions spanning three continents. METHODS: Clinical data 6,754 were supplied validation, and 6,232 complete records used. Nomogram-predicted probabilities 60-month recurrence compared with actual follow-up in two ways. First, areas under receiver operating characteristic curves (AUCs)...

10.1200/jco.2002.12.019 article EN Journal of Clinical Oncology 2002-08-01

Abstract Purpose: A better understanding of the molecular pathways underlying development epithelial ovarian cancer (EOC) is critical to identify tumor markers for use in diagnostic or therapeutic applications. The aims this study were integrate results from 14 transcript profiling studies EOC novel biomarkers and examine their expression early late stages disease. Experimental Design: database incorporating genes identified as being highly up-regulated each was constructed. Candidate...

10.1158/1078-0432.ccr-04-0073 article EN Clinical Cancer Research 2004-07-01

Abstract Background: Epigenetic alterations are common in prostate cancer, yet how these modifications contribute to carcinogenesis is poorly understood. We investigated whether specific histone prognostic for cancer relapse, and the expression of epigenetic genes altered tumorigenesis. Methods: Global levels H3 lysine-18 acetylation (H3K18Ac) lysine-4 dimethylation (H3K4diMe) were assessed immunohistochemically a cohort 279 cases. gene was silico by analysis microarray data from 23 primary...

10.1158/1055-9965.epi-10-0555 article EN Cancer Epidemiology Biomarkers & Prevention 2010-10-01

Abstract Purpose: Despite significant progress in understanding the molecular pathology of pancreatic cancer and its precursor lesion: intraepithelial neoplasia (PanIN), there remain no molecules with proven clinical utility as prognostic or therapeutic markers. Here, we used oligonucleotide microarrays to interrogate mRNA expression tissue normal pancreas identify novel pathways dysregulated development progression cancer. Experimental Design: RNA was hybridized Affymetrix Genechip HG-U133...

10.1158/1078-0432.ccr-04-1813 article EN Clinical Cancer Research 2005-05-01

Prognostic indicators in pancreatic cancer (PC) are poorly defined and difficult to quantify preoperatively, hence they may lead inappropriate patient selection for treatment. We examined the protein expression of key cell-cycle regulatory cell-signaling molecules that occur at high frequency PC assessed their relationship clinicopathologic parameters, response operative resection, outcome.We identified 348 patients with ductal adenocarcinoma influence reported prognostic factors genes...

10.1200/jco.2002.12.063 article EN Journal of Clinical Oncology 2002-11-26

Abstract The extracellular matrix (ECM) is a reservoir of cellular binding proteins and growth factors that are critical for normal cell behavior, aberrations in the ECM invariably accompany malignancies such as prostate cancer. Carcinomas commonly overexpress macrophage inhibitory cytokine 1 (MIC-1), proapoptotic antitumorigenic transforming factor–β superfamily cytokine. Here we show MIC-1 often secreted an unprocessed propeptide containing form. It variably processed intracellularly, with...

10.1158/0008-5472.can-04-3827 article EN Cancer Research 2005-03-15

Abstract Purpose: Dysregulation of cell cycle control, in particular G1-S-phase transition, is implicated the pathogenesis most human cancers, including epithelial ovarian cancer (EOC). However, prognostic significance aberrant gene expression EOC remains unclear. Experimental Design: The selected genes from pRb pathway that regulates progression, cyclin D1, p16Ink4a, E, p27Kip1, p21Waf1/Cip1, and p53, was examined a consecutive series 134 serous using immunohistochemistry results correlated...

10.1158/1078-0432.ccr-03-0751 article EN Clinical Cancer Research 2004-08-01

Abstract Prostate cancer is the most common in men. Advanced prostate spreading beyond gland incurable. Identifying factors that regulate spread of tumor into regional nodes and distant sites would guide development novel diagnostic, prognostic, therapeutic targets. The aim our study was to examine expression biological role EphB4 cancer. mRNA expressed 64 72 (89%) tissues assessed. protein found majority (41 62, 66%) tumors, 3 20 (15%) normal tissues. Little or no observed benign epithelial...

10.1158/0008-5472.can-04-2667 article EN Cancer Research 2005-06-01

Mucinous epithelial ovarian cancers (MOC) are clinically and morphologically distinct from the other histological subtypes of cancer. To determine genetic basis MOC to identify potential tumour markers, gene expression profiling 49 primary different was performed using a customised oligonucleotide microarray containing >59 000 probesets. The results show that express profile both differs overlaps with Concordant its phenotype, genes characteristic mucinous carcinomas varying origin,...

10.1038/sj.bjc.6603003 article EN cc-by-nc-sa British Journal of Cancer 2006-02-28

Docetaxel chemotherapy improves symptoms and survival in men with metastatic hormone-refractory prostate cancer (HRPC). However, approximately 50% of patients do not respond to are exposed significant toxicity without direct benefit. This study aimed identify novel therapeutic targets predictive biomarkers resistance HRPC. We used iTRAQ-mass spectrometry analysis proteins associated the development using Docetaxel-sensitive PC3 cells Docetaxel-resistant PC3-Rx developed by dose escalation....

10.1158/0008-5472.can-08-4901 article EN Cancer Research 2009-09-23

Study Type - Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does study add? Only 30-35% patients with positive surgical margins after radical prostatectomy develop recurrent disease. Adjuvant radiotherapy reduces rate biochemical relapse or metastasis improves overall survival prostatectomy. Various pathological factors, such as location extent margins, have been proposed possible prognostic factors in men margin-positive prostate cancer, however, recent...

10.1111/j.1464-410x.2011.10572.x article EN BJU International 2011-10-12

PURPOSE: A postoperative nomogram for prostate cancer was developed at Baylor College of Medicine. This uses readily available clinical and pathologic variables to predict 7-year freedom from recurrence after radical prostatectomy. We evaluated the predictive accuracy when applied patients four international institutions. PATIENTS AND METHODS: Clinical data 2,908 were supplied validation, 2,465 complete records used. Nomogram-predicted probabilities compared with actual follow-up in two...

10.1200/jco.2002.20.4.951 article EN Journal of Clinical Oncology 2002-02-15

Abstract BACKGROUND The role of the bone morphogenetic protein (BMP) pathway in prostate cancer (PC) is unclear. This study aimed to characterize aspects BMP PC by assessing BMP2, Smad8, and Smad4 expression normal, hyperplastic, malignant tissue, correlate findings with progression PC. METHODS Radical prostatectomy (RP) specimens from 74 patients clinically localized (median follow‐up 51 months, range 15–152), 44 benign prostatic hypertrophy (BPH) lesions, 4 normal prostates (NPs) were...

10.1002/pros.10361 article EN The Prostate 2003-12-11
Coming Soon ...